SALSA

The SALSA study aims to assess the impact of semaglutide (Ozempic®, Wegovy®, and Rybelsus®) on self-reported alcohol consumption and weight among individuals with type 2 diabetes, obesity, and/or metabolic syndrome, including those living with or without HIV, in two outpatient clinics. These clinics include the Diabetes Health Centre and the John Ruedy Clinic within St. Paul’s Hospital.

 

Among individuals who take semaglutide to manage type 2 diabetes and weight loss, secondary impacts to alcohol consumption have been observed, though in a limited population. This study aims to expand research on this relationship to include people living with HIV and observe how these individuals are uniquely affected.

STUDIES MENU

Are you eligible to participate?

You are eligible to participate in the SALSA study if you are:

  • Are aged 19 years or older
  • Have been prescribed semaglutide for the management of type 2 diabetes or for weight loss
  • Have received your initial prescription for semaglutide treatment by your physician.
  • Have at least six months of follow-up since starting semaglutide treatment
  • Are willing and able to provide informed consent for study participant
  • Are able to complete the survey in English

What does my participation involve?

If you are eligible to participate in the study, you will be asked to complete one survey, which will take approximately 20 minutes to complete.

You will receive $30 after completing the survey.

The survey will include questions about your personal background and characteristics, semaglutide use and your perspective about taking the medication, alcohol and tobacco use, as well as medical information related to your height, weight, and any chronic conditions.

How do I participate?

If you want to do the survey by registering online, your next steps are:

CONSENT FORM

Click the “Register for the Study” button below to read through the study consent form and start the registration process to complete the survey.
Register for the Study
CONSENT FORM

SOME QUESTIONS

After reading through the consent form, if you do not have any questions and agree to participate in the study, click the ‘Continue’ button to answer the study registration questions.

SOME QUESTIONS

ELIGIBILITY

Your answers to the registration questions will determine if you are eligible to participate in the study and complete the survey. You may also indicate your preferred method for taking the survey. Our study team will verify your eligibility and contact you with the next steps.

ELIGIBILITY

COMPLETE THE SURVEY

  1. If you selected to do the survey online by yourself: Once you are invited to participate in the study and would like to begin, or if you have already started the survey but haven’t completed it, click on the “Continue to the Survey” button. This will allow you to start or continue the survey where you left off after entering your eligibility information.
  2. If you would prefer to do the survey either in-person or over the phone with the help of a research assistant: Once you are invited to participate in the study, you are able to schedule an appointment during our hours of operation (Monday-Friday 8:00am to 4:00pm). In-person interviews will be offered at St. Paul’s Hospital out of the Diabetes Health Centre.
Continue to the Survey
COMPLETE THE SURVEY

Note

The information you provide for this study will not be stored on the device you complete the survey on. Your responses will be encrypted before being sent to our secure server. Please ensure you are using a private internet network to reduce the risk of your information being seen by others. If you do not have a private internet network available to you, you can still participate in this study over the phone or in person by giving us a call at: (604) 806-8477 ext. 66272 or emailing us at salsa@bccfe.ca
If you want to do the survey by registering over the phone, your next steps are:

CONSENT FORM

Call (604) 806-8477 ext. 66272 to speak with someone from our study team who will help you review the study consent form and start the registration process to complete the survey.

CONSENT FORM

SOME QUESTIONS

The team member will read through the consent form with you. If you do not have any questions and agree to participate in the study, you will then be guided through the study registration questions.

SOME QUESTIONS

ELIGIBILITY

Your answers to the registration questions will determine if you are eligible to participate in the study and complete the survey. You may also indicate your preferred method for taking the survey. Another member of our study team will verify your eligibility and contact you with the next steps.

ELIGIBILITY

COMPLETE THE SURVEY

  1. If you selected to do the survey online by yourself: Once you are invited to participate in the study and would like to begin, or if you have already started the survey but haven’t completed it, click on the “Continue to the Survey” button. This will allow you to start or continue the survey where you left off after entering your eligibility information.
  2. If you would prefer to do the survey either in-person or over the phone with the help of a research assistant: Once you are invited to participate in the study, you are able to schedule an appointment during our hours of operation (Monday-Friday 8:00am to 4:00pm). In-person interviews will be offered at St. Paul’s Hospital out of the Diabetes Health Centre.
Continue to the Survey
COMPLETE THE SURVEY

Why should I participate?

We do not think taking part in this study will help you directly. However, you will help us understand more about specific impacts of semaglutide and alcohol use among people living with HIV and, in the future, others may benefit from what we learn in this study.

Study documents

01.
Distress Support Resources
Download PDF
02.
Detoxification and Rehabilitation Programs
Download PDF
03.
Resources for PWH
Download PDF
04.
Participant Informed Consent Form
Download PDF
05.
Culturally Safe and Trauma-Informed Cultural Services (Source: FNHA)
Download PDF

Contact

For more information or to participate, please contact the SALSA study team by calling (604) 806-8477 ext. 66272 or emailing salsa@bccfe.ca.

Study team

Principal Investigator

Dr. Julio SG Montaner Executive Director and Physician-in-Chief BC Center for Excellence in HIV/AIDS, Dr. Gregory Bondy Specialist John Ruedy Clinic BC Center for Excellence in HIV/AIDS and Providence Healthcare

Co-Investigators

  • Dr. Robert Hogg
  • Dr Silvia Guillemi
  • Dr. Marianne Harris
  • Dr. Katherine Kooij
  • Dr. Surita Parashar

Study staff

  • Study Coordinator: Marisa Leach

Recruitment materials

Study recruitment poster
Scroll to Top

The British Columbia Centre for Excellence in HIV/AIDS Laboratory has discontinued gp-41 resistance testing as T-20 (enfuvirtide/Fuzeon) is no longer available in Canada as of March 31, 2025

Start typing and press enter to search